Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

Lupus skin symptoms improved within 4 weeks for some patients switching from placebo

Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?

Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated

BIIB Oct 2026 245.000 call (BIIB261030C00245000) Stock Price, News, Quote & History

BIIB Oct 2026 222.500 put (BIIB261002P00222500) Stock Price, News, Quote & History

1 Profitable Stock Worth Investigating and 2 We Ignore

HLS Therapeutics Announces Board of Directors Changes

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?

Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack

10 Health Care Stocks Whale Activity In Today’s Session

How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data

Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets

Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva